M ultiple sclerosis (MS) affects approximately 400,000
Americans. 1 Most patients are diagnosed between 20 and 50 years of age, and the disease develops in twice as many women as men. 1 MS is characterized by scattered areas of inflammation, demyelination, and axonal injury affecting the brain, optic nerves, and spinal cord. 2 Inflammatory demyelination can be accompanied by clinical symptoms, termed relapses, followed by some degree of recovery, producing the classic relapsing-remitting MS (RRMS) seen early in the disease. 2 Secondary progressive MS (SPMS) occurs when persistent signs of central nervous system (CNS) dysfunction develop after a relapse, and the disease progresses between relapses.
2 RRMS develops into secondary progressive MS in 50% of patients within 10 years and 75% of patients within 25 years. 1 Primary progressive MS (PPMS) occurs when the clinical course is gradually progressive and is the diagnosis in approximately 20% of MS cases. 1 Clinical course and disability vary between patients and depend on MS disease type. 2 The medical and pharmacy costs of MS are substantial. Pope et al. (2002) analyzed the cost of MS in beneficiaries with private insurance, Medicare, or Medicaid. Excluding prescription drug costs from all comparisons because Part D coverage was not in effect at the time of the study, members with MS enrolled in private insurance had 3 times the average all-cause medical expenditures compared with non-MS members ($6,329 vs. $2,001). 3 Medicare members with MS had double the medical expenditures compared with members without MS ($13,048 vs. $6,006). Finally, members with MS covered by Medicaid had 2.5 times the medical costs compared with members without MS ($10,358 vs. $4,111). In the private insurance and Medicaid cohorts, prescription drug costs were also higher in the MS group. 3 Using survey data and estimated costs for a random sample of participants in the North American Research Committee on MS (NARCOMS) patient registry who reported use of 1 or more of the 4 MS biologic agents, Kobelt et al. (2006) estimated that the total mean annual direct (inpatient and outpatient services, prescriptions) and indirect costs (loss of productivity, work loss or reduction) of MS were $47,215 per patient (in 2004 dollars). 4 Direct medical and nonmedical costs including "informal care from family and friends" accounted for $29,634 per patient per year (PPPY). 4 The single largest expenditure in the direct cost category was MS biologics at $16,050 PPPY or 34.0% of the overall direct and indirect costs. 4 Price inflation for existing drugs and the introduction of new agents for MS promise to further increase the cost of MS and present a growing challenge for payers.
In 4 The difference in utilization of biologic agents explains some of the disparity in PPPY pharmacy expenditures on MS biologics between NARCOMS ($16,050) and Asche et al. ($4,436) , despite older data (from 2004) in the NARCOMS study. 4 Second, the analysis by Asche et al. (Table 1) . Combined medical and pharmacy costs increased by nearly 27% from $29,652 PPPY in 2006 to $37,592 ( Table 1 ). The cost trends presented here are for a fixed cohort followed over time and may be confounded by worsening disease resulting in increased medical and pharmacy expenditures. However, pharmacy biologic expenditures are unlikely to be influenced by worsening disease as combination biologic therapy is not approved by the U.S. Food and Drug Administration (FDA).
Price inflation has led to an increasing cost burden on patients as well. 6 An analysis of internal data from our 2006 to 2010 commercial book of business of approximately 9.0 million members indicates that mean member out-of-pocket cost share per prescription claim for MS therapies nearly doubled from 2006 to 2009 (Table 2 ). Prescription claims in the analysis of cost per prescription were adjusted by days supply (0-34 days = 1 claim, 35-68 days = 2 claims, 69-120 days = 3 claims). These data support the findings of Asche et al. 5 and Kunze et al. 6 regarding the growing medical and pharmacy costs of MS.
Cost-Effectiveness of MS Biologics
The cost-effectiveness of the MS biologics has been analyzed in previous studies in JMCP with conflicting results. QALY. IFN beta-1a IM, IFN beta-1b SC, and IFN beta-1a SC had costs per QALY of $303,968, $310,691, and $416,301, respectively. 9 Payers can expect cost-effectiveness of the MS biologics to erode as price inflation continues.
Recent Drug Approvals for MS Enlarge Opportunity for Utilization Management
The pharmacy costs of managing MS are likely to increase further with the approval of new therapies. Dalfampridine was approved by the FDA in January 2010 to improve walking in patients with MS as demonstrated by an increase in walking speed. 10 Dalfampridine does not prevent MS relapses; instead, dalfampridine is theorized to exert its effects on walking ability by blocking potassium channels and improving conduction in motor neurons damaged by MS. 10 Dalfampridine clinical trials included patients with PPMS and thus may expand the pool of MS patients eligible for treatment with prescription agents. The average wholesale price (AWP) of a 10 mg dalfampridine tablet is $21.12, and 1 month of therapy would cost $1,267.20. 11 This cost would be in addition to, rather than replacing, any cost associated with MS biologics pharmacotherapy.
In September 2010, fingolimod was approved by the FDA as the first oral MS agent, with the specific indication to reduce relapses and delay disability progression in patients with relapsing forms of MS. 12 The AWP of fingolimod is $158 per capsule or $4,740 per month. 11 The cost of fingolimod is significantly higher than those of the competing injectable MS biologics.
MS is a devastating disease, and patients should be managed with approved therapies to reduce relapses and manage disability. However, payers must be prepared to manage the MS category to ensure cost-effective use. MS drug class maturation provides payers with greater opportunities to derive cost savings through tools like formulary, benefit design, and utilization management programs.
Clinical guidelines presently recommend initiating therapy in patients with RRMS using either an IFN or glatiramer, and the guidelines do not prefer one IFN product over another. 13, 14 Comparative trials have shown a possible advantage in reduced relapse rates with IFN beta-1a SC or IFN beta-1b SC compared with IFN beta-1a IM. 15 However, the effect on long-term disability between these agents is unclear. 15 Comparative data among IFN beta-1a SC, IFN beta-1b SC, and glatiramer have demonstrated comparable efficacy in reducing relapse rates.
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The similar efficacy and safety of approved therapies presents an opportunity for payers to prefer 1 or 2 agents on the formulary. Payers should ensure the tier differential is substantial enough to encourage use of preferred products and shift market share to formulary agents. Data are limited on MS biologics in other types of MS, and no MS biologic or fingolimod has been shown to be effective in PPMS.
Utilization management programs present another opportunity to promote safe use and control MS costs.
Step-therapy programs can require trial of one agent prior to another and may prevent concurrent use of 2 relapse-preventing agents, which has not been evaluated for safety or effectiveness. Patients shown to be intolerant to or failing preferred agents could then be approved for nonpreferred therapies. Prior authorization (PA) programs may be implemented to verify appropriate use of fingolimod and other MS agents for only types of MS for which there are efficacy and safety data available. Coverage of dalfampridine should be limited to patients with MS and renewed upon demonstration of efficacy. Responder rates in dalfampridine pivotal trials ranged from 35%-43% compared with 8%-9% for placebo. 16, 17 Response generally occurred quickly and was sustained during the trial. 16, 17 PA programs should require documentation of efficacy 2 or more months after initiation of therapy. Dalfampridine has been associated with safety concerns including an increased risk of seizure. 10 Patients failing to demonstrate efficacy should not be approved for continuing therapy.
Benefit Design Considerations and Member Cost Share
Benefit designs including a fourth cost-share tier or specialty cost-share tier are becoming more common. Part of the function of a specialty cost-share tier is to differentiate specialty products and increase cost share to members. However, payers should exercise caution when utilizing a specialty tier and associated increased cost share. Gleason et al. (2009) examined the rate of prescription abandonment in association with member cost share. 18 Members paying $100 or less per prescription for MS medications were compared with patients paying more than $100. The analysis found a significantly higher associated rate of prescription abandonment for MS patients paying more than $200 per prescription compared with patients paying $100 or less. 18 Our benchmark analysis of pharmacy and medical claims data showed that the mean out-of-pocket patient expenditure per prescription claim for MS agents increased from $48 per claim in 2006 to $82 in 2009 (Table 2) . 7 Although the mean patient expenditure per prescription appears higher in 2010 than in 2009, the data are through 3 quarters and therefore are not representative of an entire year. Median patient expenditures per prescription are roughly one-half the mean expenditure and have risen minimally from $25 in 2006 to $30 in 2009. The discrepancy between mean and median patient expenditure per prescription claim is likely the result of 2 factors. First, Gleason et al. found that 13.8% of patients filling prescriptions for MS biologic drugs paid more than $200 per prescription, and 5.4% paid more than $500 per prescription; these higher costs skew the mean upward relative to the median. Second, members pay higher out-of-pocket amounts early in the year when deductibles have not been met ( Table 2) . 7 Nonadherence to therapy may increase the risk of relapse and associated disability. Payers should consider setting a maximum out-of-pocket limit of between $100 and $150 per prescription when utilizing a specialty tier for MS biologic agents.
MS is a potentially disabling disease, but treatment options are available. The article by Asche et al. 5 and others like it highlight the escalating costs associated with MS management. Price inflation continues to be the primary driver of increased pharmacy costs for MS patients. Opportunities exist for payers to manage the MS categories and control cost. Preferring select agents on formulary, developing utilization management programs to promote patient safety, and encouraging use of preferred agents and specialty pharmacies all provide opportunities to optimize clinical and service outcomes at the lowest cost.
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